Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Label Revisions Ordered for Xtandi, Paxlovid, and More Drugs
April 9, 2025
- Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
April 9, 2025
- FPMAJ Renews Call for Scrapping Off-Year Drug Price Revision: Diet Hearing
April 9, 2025
- Japan Economic Minister Akazawa to Lead Tariff Talks with US
April 9, 2025
- PMDA Announces Guidance on “Competing Products” in Regulatory Review
April 8, 2025
- MHLW Now Soliciting Bids for FY2025 Budget Projects to Fight Drug Lag/Loss
April 8, 2025
- Ishiba, Trump Agree to Appoint Ministers for Tariffs Talks
April 8, 2025
- Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
- Ishin Prods Govt to End Fee Incentives for Generic Use, Minister Says Topic Up for Chuikyo Discussions
April 7, 2025
- Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
April 7, 2025
- Shingles Shots Added to NIP, HPV Catch-Up Program Extended: MHLW
April 7, 2025
- LDP’s New Fiscal Reform HQ to Release Draft Report by Late May
April 4, 2025
- 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
April 4, 2025
- Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
- JIHS Now Up and Running as Japan Version of CDC
April 3, 2025
- PMD Act Amendment to Enter Diet Debate; Parallel Deliberations Planned for Bill to Scrap Off-Year Revisions
April 3, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- GSK’s Shingrix Buttresses Label with Long-Term Data
April 2, 2025
- MHLW Says It Will Handle Info Disclosure Requests as per Rules
April 2, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…